WFXG: ImmunoForge to Accelerate CNS Drug Development with Innovative BBB Shuttle Platform 'LMT15'
ImmunoForge Co., Ltd., a clinical-stage biopharmaceutical company specializing in treatments for rare and muscular diseases, is poised to redefine Central Nervous System (CNS) drug delivery with its ...
ImmunoForge to Accelerate CNS Drug Development with Innovative BBB Shuttle Platform 'LMT15'
CNS-3D Brain Organoids Predict Clinical Seizure Liability Central nervous system (CNS) toxicity accounts for 25% of safety failures across drug discovery a | Drug Discovery And Development ...
Nasdaq: Polyrizon Ltd. Reports Promising Preclinical Results for CNS Drug Delivery Using Hydrogel-Based Trap & Target Platform
Polyrizon Ltd. Reports Promising Preclinical Results for CNS Drug Delivery Using Hydrogel-Based Trap & Target Platform
The CNS field has been waiting far too long for a true breakthrough in brain-targeted drug delivery. Despite decades of R&D and countless promising candidates, the blood-brain barrier remains the ...
Seeking Alpha: Supernus Pharmaceuticals: Derisked CNS Drug Portfolio Offers Attractive Buying Opportunity
Labroots: CNS Delivery in Drug Development and Toxicology: Best Practices and Recent Advances
Central Nervous System (CNS) therapies have significantly progressed in the last decade, propelled by emerging treatment modalities including gene therapies. Neurological indications remain amongst ...
CNS Delivery in Drug Development and Toxicology: Best Practices and Recent Advances
Morningstar: CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions
CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions
Morningstar: The International Society for CNS Drug Development (ISCDD) Honors Suresh Durgam, MD, with Prestigious Leadership Award at 24th Annual Meeting